Merck KGaA: Pipeline, Products, Performance, Potential

Table of Contents

• Latest Results
• EXECUTIVE SUMMARY
  • Introduction
  • Financial Performance 2008
    • Current Financial Position
    • Business Segment Performance
    • Geographic Segment Performance
  • Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
    • Discontinued Agreements
  • Employees
  • Product Performance Forecasts
    • Key Products
    • Discontinued Products
  • Pipeline Analysis
    • Discontinued R&D projects
  • Conclusions
• THERAPEUTIC AREA FOCUS
• R&D PIPELINE
• NEUROLOGY
  • Marketed Products
    • Novantrone
    • Rebif
  • R&D Projects
    • Mylinax/Movectro
    • Safinamide
  • Growth Forecast
• CARDIOMETABOLIC CARE
  • Marketed Products
    • Bisoprolol products (Concor & others)
    • Metformin products (Glucophage & others)
    • Praxilene/Dusodril
    • Thyroid products (Euthyrox and others)
  • R&D Projects
  • Growth Forecast
• RE PRODUCTIVE HEA LTH
  • Marketed Products
    • Cetrotide
    • Crinone
    • Gonal-f
    • Luveris
    • Metrodin/Metrodin HP/Fertinex
    • Ovidrel/Ovitrelle
    • Pergoveris
    • Others
  • R&D Projects
    • Hyperglycosylated r-hFSH
  • Growth Forecast
• ONCOLOGY
  • Marketed Products
    • Erbitux
    • UFT/Uftoral
  • R&D Projects
    • Adecatumumab (MT201)
    • AS703026
    • AS703569
    • ASONEP
    • Cilengitide
    • EMD 521873
    • EMD 525797
    • EMD 534085
    • IMO-2055
    • Stimuvax/L-BLP25
    • Survivac
    • Tucotuzumab celmoleukin (EMD 273066)/273063
  • Growth Forecast
• ENDOCR INOLOGY
  • Marketed Products
    • Kuvan/Phenoptin
    • Saizen
    • Serostim/Zorbtive
  • Others
  • R&D Projects
    • ARX 201
    • Tesamorelin
  • Growth Forecast
• AUTOIMMUNE / INFLAMMATORY
  • Marketed Products
  • R&D Projects
    • Atacicept
    • Fibroblast growth factor 18
  • Growth Forecast
• OTHER
  • Marketed Products
    • Central Nervous System
      • Campral
      • Cyanokit
      • Neurobion
    • Dermatology
      • Frone
• APPENDIX 1 - FINANCIAL PER FORMANCE
  • Full Year Results 2008
• APPENDIX 2 - KE Y AGREE MENTS
  • Abbott
  • AEterna Zentaris
  • Alkermes Inc
  • Ambrx Inc
  • Amgen
  • Apitope Technology Ltd.
  • Archemix Corp
  • Berlex Laboratories
  • Bioject Medical Technologies Inc
  • BioMarin Pharmaceutical Inc
  • Bionomics Ltd.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Cellular Genomics Inc (CGI)
  • Cenix BioScience
  • Chemgenex Pharmaceuticals
  • Chi-Med
  • Clinical Data Inc
  • Compugen Ltd.
  • Dainippon Sumitomo Pharma
  • Eli Lilly
  • Flamel Technologies SA
  • Gene Logic Inc
  • Idera Pharmaceuticals Inc.
  • ImClone Systems Incorporated
  • Immunicon Corporation
  • IVAX Corporation
  • KineMed Inc
  • Lpath Inc
  • Meldex International
  • MultiCell Technologies Inc.
  • Micromet AG
  • Nautilus Biotech
  • Nitec Pharma AG
  • Oncothyreon Inc
  • Organon
  • OSI Pharmaceuticals Inc.
  • Paratek Pharmaceuticals Inc.
  • Pfizer
  • Provenance Biopharmaceuticals Corp.
  • Rigel Pharmaceuticals
  • Santhera Pharmaceuticals AG
  • Schering-Plough
  • Syntonix Pharmaceuticals Inc.
  • Taiho Pharmaceutical Co. Ltd.
  • Takeda
  • TargeGen Inc
  • Theratechnologies Inc.
  • Wyeth/Columbia Laboratories Inc.
  • ZymoGenetics Inc
• APPENDIX 3 - INFRASTRUCTURE
  • Research And Development Facilities
  • Manufacturing Facilities
• APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
  • Subsidiaries
  • Joint-venture Companies
• APPENDIX 5 - PRODUCT INDEX

INDEX OF TABLES

• Principal Operating Results
• Capital Expenditure By Business Area
• Capital Expenditure By Geographical Area
• Pharma R&D To Total R&D
• R&D Expenditure By Business Area
• R&D Expenditure By Geographical Area
• Sales By Business Area
• Operating Income (Loss) By Business Area
• Sales By Destination
• Net Operating Assets By Business Area
• Employees By Geographical Area (Yearly Average)
• Recent Product Approvals
• Major Products, Therapeutic Areas and Sales
• Major Neurology Products, 2008
• Major CardioMetabolic Care Products, 2008
• Major Reproductive Health Products, 2008
• Major Oncology Products, 2008
• Major Autoimmune/Inflammatory Products, 2008
• Major European Subsidiaries
• Major North American Subsidiaries
• Major Latin American Subsidiaries
• Major Asia, Africa, Australasia Subsidiaries

INDEX OF CHARTS

• Sales, Costs and Operating Income
• Capital Expenditure By Business Area, 2008
• Capital Expenditure By Geographical Area, 2008
• R&D Expenditure By Business Area, 2008
• Sales By Business Area
• Sales By Destination
• Employees By Geographical Area (Yearly Average), 2008
• Sales of Current Major Products (2003A-2013E)
• Top Selling Products, 2008
• Rebif Sales (2003A-2013E)
• Movectro Sales (2010E-2015E)
• Safinamide Sales (2009E-2015E)
• Bisoprolol Products Sales (2003A-2013E)
• Glucophage/metformin products Sales (2003A-2013E)
• Thyroid products (Euthyrox and others) Sales (2003A-2013E)
• Gonal-f Sales (2003A-2013E)
• Ovidrel Sales (2003A-2013E)
• Erbitux Sales (2003A-2013E)
• Stimuvax Sales (2011E-2015E)
• Endocrinology Products, 2008
• Kuvan/Phenoptin Sales (2008E-2015E)
• Saizen Sales (2003A-2013E)
• Serostim Sales (2003A-2013E)
• Campral Sales (2003A-2013E)
• Neurobion Sales (2003A-2013E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity